Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q3 EPS of $1.51, versus $1.15 reported last year. Revenue for the quarter ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE